{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"title":"Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"title":"Cycle 7"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"Within 24 hours from the end of study treatment infusion in all cycles, including maintenance ((1 cycle: 21 or 28 days depending on the chemotherapy selected); up to approximately 2.5 years)","title":"Percentage of IRRs Regardless of Grade by Cycle","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}